New York, NY -- (SBWIRE) -- 12/09/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Arca Biopharma Inc (NASDAQ:ABIO), PDL BioPharma Inc (NASDAQ:PDLI), Medical Marijuana Inc (OTCMKTS:MJNA), Finisar Corporation (NASDAQ:FNSR)
Arca Biopharma Inc (NASDAQ:ABIO) showed a volume of 2.11 million shares by the end of last trade whereas the average volume of the stock remained 1.56 million shares. The stock opened the session at $1.61 but then moved to $1.55. At that price, the stock showed a negative performance of -6.06%. ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company's principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). The Company has collaborated with LabCorp to develop the Gencaro Test, a companion test for the genetic markers that may predict clinical response to Gencaro.
Will ABIO Get Buyers Even After The Recent Rally? Find Out Here
PDL BioPharma Inc (NASDAQ:PDLI) opened the session at $8.19 and closed the session at $8.29. The stock showed a positive performance of 2.35% in previous trading session. Traded with volume of 2.83 million shares in the prior session and the average volume of the stock remained 2.80 million shares. PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014.
For How Long PDLI will fight for Profitability? Read This Trend Analysis report
Medical Marijuana Inc (OTCMKTS:MJNA) opened the session at $0.11 and closed the session at $0.114. The stock showed a positive performance of 4.11% in previous trading session. Traded with volume of 3.56 million shares in the prior session and the average volume of the stock remained 8.50 million shares. The beta of the stock remained 5.90. Medical Marijuana Inc. (MJNA) is the publicly held company vested in the medical marijuana and industrial hemp markets. It is comprised of a diversified portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries. These products range from patented and based cannabinoid products, to whole plant or isolated high value extracts specifically manufactured and formulated for the pharmaceutical,
Why Should Investors Buy MJNA After The Recent Gain? Just Go Here and Find Out
Finisar Corporation (NASDAQ:FNSR) the stock advanced 0.27% and finished the session at $21.82. Traded with volume of 11.46 million shares in the prior session and the average volume of the stock remained 2.76 million shares. The beta of the stock remained 2.53. Finisar Corporation (Finisar) is a provider of optical subsystems and components that are used in data communication and telecommunication applications. The Company’s optical subsystems consist primarily of transmitters, receivers, transceivers, transponders and active optical cables that provide the fundamental optical-electrical, or optoelectronic,
Will FNSR Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)